fingolimod pharmascience 0,5 mg trde kapsule
fingolimod - kapsula, trda - fingolimod 0,5 mg / 1 kapsula - fingolimod
gilenya
novartis europharm limited - fingolimod hidroklorid - multiple skleroza - imunosupresivi - gilenya je označeno kot eno bolezen spreminjanje terapije v zelo aktivna recidivno nakazila multiplo sklerozo, za naslednje skupine odraslih bolnikov in pediatričnih bolnikih, starih 10 let in več:bolniki z zelo aktivna bolezen kljub popolno in ustrezno tečaj zdravljenja z vsaj eno bolezen spreminjanje terapije (za izjeme in informacije o izpiranja obdobja glej točki 4. 4 in 5. orpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.
fingolimod accord
accord healthcare s.l.u. - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi, selektivno imunosupresivi - navedeno kot eno bolezen spreminjanje terapije v zelo aktivna recidivno nakazila multiplo sklerozo, za naslednje skupine odraslih bolnikov in pediatričnih bolnikih, starih 10 let in več:bolniki z zelo aktivna bolezen kljub popolno in ustrezno tečaj zdravljenja z vsaj eno bolezen spreminjanje therapyorpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.
fingolimod mylan
mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1)orpatients s hitro razvijajočimi se hudo recidivno nakazila multiplo sklerozo, opredeljeno z 2 ali več onemogočanje zagonov v enem letu, in z 1 ali več gadolinium krepitev poškodbe na možganih, mri ali znatno povečanje t2 lezije obremenitvi, kot je v primerjavi s predhodnim zadnjih mri.
fingolimod mylan
mylan ireland limited - fingolimod hidroklorid - multiplo sklerozo, recidivno-nakazila - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 in 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
zeposia
bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
duotab obložene tablete
krka, d.d., novo mesto - askorbinska kislina (vitamin c); cianokobalamin (vitamin b12); vseracemni-alfa-tokoferilacetat; folna kislina (vitamin b9); holekalciferol (vitamin d3); kalcijev pantotenat; nikotinamid; piridoksinijev klorid; riboflavin (vitamin b2); tiaminijev nitrat; vitamin a - obložena tableta - askorbinska kislina (vitamin c) 60 i.e. / 1 tableta cianokobalamin (vitamin b12)0,003 i.e. / 1 tableta vseracemni-alfa-tokoferilacetat10 i.e. / 1 tableta folna kislina (vitamin b9)0,4 i.e. / 1 tableta holekalciferol (vitamin d3)200 i.e. / 1 tableta kalcijev pantotenat5 i.e. / 1 tableta nikotinamid13 i.e. / 1 tableta piridoksinijev klorid2 i.e. / 1 tableta riboflavin (vitamin b2)1,2 i.e. / 1 tableta tiaminijev nitrat1 i.e. / 1 tableta vitamin a5000 i.e. / 1 tableta; cianokobalamin (vitamin b12) 0,003 i.e. / 1 tableta vseracemni-alfa-tokoferilacetat10 i.e. / 1 tableta folna kislina (vitamin b9)0,4 i.e. / 1 tableta holekalciferol (vitamin d3)200 i.e. / 1 tableta kalcijev pantotenat5 i.e. / 1 tableta nikotinamid13 i.e. / 1 tableta piridoksinijev klorid2 i.e. / 1 tableta riboflavin (vitamin b2)1,2 i.e. / 1 tableta tiaminijev nitrat1 i.e. / 1 tableta vitamin a5000 i.e. / 1 tableta; vseracemni-alfa-tokoferilacetat 10 i.e. / 1 tableta folna kislina (vitamin b9)0,4 i.e. / 1 tableta holekalciferol (vitamin d3)200 i.e. / 1 tableta kalcijev pantotenat5 i.e. / 1 tableta nikotinamid13 i.e. / 1 tableta piridoksinijev klorid2 i.e. / 1 tableta riboflavin (vitamin b2)1,2 i.e. / 1 tableta tiaminijev nitrat1 i.e. / 1 tableta vitamin a5000 i.e. / 1 tableta; folna kislina (vitamin b9) 0,4 i.e. / 1 tableta holekalciferol (vitamin d3)200 i.e. / 1 tableta kalcijev pantotenat5 i.e. / 1 tableta nikotinamid13 i.e. / 1 tableta piridoksinijev klorid2 i.e. / 1 tableta riboflavin (vitamin b2)1,2 i.e. / 1 tableta tiaminijev nitrat1 i.e. / 1 tableta vitamin a5000 i.e. / 1 tableta; holekalciferol (vitamin d3) 200 i.e. / 1 tableta kalcijev pantotenat5 i.e. / 1 tableta nikotinamid13 i.e. / 1 tableta piridoksinijev klorid2 i.e. / 1 tableta riboflavin (vitamin b2)1,2 i.e. / 1 tableta & - multivitamini in drugi minerali ter kombinacije
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - druga zdravila na živčnem sistemu - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
besponsa
pfizer europe ma eeig - inotuzumab ozogamicin - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - besponsa je indicirana kot monoterapija za zdravljenje odraslih z relapsom ali ognjevzdržnim cd22-pozitivnim prekurzorjem celice b celične limfoblastne levkemije (all). odraslih bolnikov s philadelphia kromosom pozitiven (ph+) relapsed ali ognjevzdržni b celic predhodnik vse bi bilo zaman zdravljenje z vsaj 1 tirozin kinaza serotonina (tki).
ogluo
tetris pharma b.v - glukagon - sladkorna bolezen - trebušne slinavke hormonov, glycogenolytic hormonov - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.